Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s166399
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Eribulin for the Treatment of Metastatic Breast Cancer: An Update on Its Safety and Efficacy

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2015English

Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life

SpringerPlus
Multidisciplinary
2016English

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE

Oncologist
Cancer ResearchMedicineOncology
2018English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Choosing Treatment for Metastatic Breast Cancer.

BMJ
1982English

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

Oncology
MedicineCancer ResearchOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy